Is Kabra Drugs Ltd (524322) a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Kabra Drugs Ltd is a below average quality company .

Is Kabra Drugs Ltd (524322) undervalued or overvalued?

The key valuation ratios of Kabra Drugs Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Kabra Drugs Ltd (524322) share price return in the past 10 years?

Kabra Drugs Ltd share price has appreciated 9.4% annually (CAGR) over the past ten years.

Is Kabra Drugs Ltd (524322) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Kabra Drugs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Kabra Drugs Ltd (524322)?

Company share prices are keep on changing according to the market conditions. The current trading price of Kabra Drugs Ltd (524322) on 30-Apr-2026 16:59:59 at 16:59 is 26.03.

What is the P/E ratio of Kabra Drugs?

The latest standalone P/E ratio of Kabra Drugs as of 30-Apr-2026 is 14.36.

What is the P/B ratio of Kabra Drugs Ltd (524322)?

The latest standalone P/B ratio of Kabra Drugs Ltd (524322) as of 30-Apr-2026 is 2.16.

What is the 52-week high and low of Kabra Drugs Ltd (524322)?

The 52-week high of Kabra Drugs Ltd (524322) is Rs. 35.52 and the 52-week low is Rs. 10.56.

Kabra Drugs Ltd (524322) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Kabra Drugs Ltd (524322)
Brand: Kabra Drugs

Kabra Drugs Ltd (524322) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Kabra Drugs Ltd (524322)

BSE: 524322 NSE:

Key Metrics

Market Cap

₹62 Cr.

P/E Ratio

14.36

Price to Book (P/B)

2.16

Price to Sales (P/S)

1.08

EV/EBITDA

10.68

Return on Capital Employed (ROCE)

-7.78%

Current Price

₹26

Return on Equity (ROE)

-9.36%

Return on Assets (ROA)

-7.29%

Operating Profit Margin

Net Profit Margin

-INF%

Gross Profit Margin

Book Value per Share

₹12.1

Sales Growth (YoY)

NA%

Sales Growth (3 Years)

NA%

Operating Profit Growth (1 Year)

NA%

Operating Profit Growth (3 Years)

N/A%

Net Profit Growth (1 Year)

NA%

52-Week Low / High

₹11 / 36

Net Profit Growth (3 Years)

N/A%

Dividend Yield

0.00%

Promoter Holding

0.00%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Stock return of Kabra Drugs Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 9.4% based on the current price.

Q.1 Revenue growth of Kabra Drugs Ltd?

Kabra Drugs Ltd revenue growth is 0% for FY-2025, which is below its 3-year CAGR of NA%, indicating slower growth.

Q.1 Which industry/sub-sector does Kabra Drugs Ltd belong to?

Kabra Drugs Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.1 Promoter shareholding and pledge status of Kabra Drugs Ltd?

Promoters hold 0.00% of the Kabra Drugs Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Kabra Drugs Ltd vs industry peers?

Kabra Drugs Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 8.24%, indicating slower growth and losing its market share.

DeciZen - make an informed investing decision on Kabra Drugs

Based on:

Data

M-Cap below 100cr DeciZen not available

Kabra Drugs stock performance

Key Ratios

Is Kabra Drugs Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	5.8%	7.5%	-80.1%	-19.7%	-8.8%	-27.3%	-28%	-52.6%	-42.7%	-7.8%	-
Value Creation Index ⓘ	-0.6	-0.5	-6.7	-2.4	NA	NA	NA	NA	NA	-1.6	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	9.7	7.6	2	0	0	0	0	0	0	0	57
Sales YoY Gr.	-	-21.1%	-73.6%	-100%	NA	NA	NA	NA	NA	NA	-
Adj EPS ⓘ	0.1	0.3	-3.9	-0.4	-0.1	-0.4	-0.4	-0.8	-1.7	-0.5	1.8
YoY Gr.	-	400%	-1386.7%	NA	NA	NA	NA	NA	NA	NA	-
BVPS (₹) ⓘ	6	5.8	0.5	0.1	-0.1	-0.5	-0.9	-1.7	-3.3	10.4	12.1
Adj Net Profit ⓘ	0	0.1	-1.7	-0.2	-0.1	-0.2	-0.2	-0.3	-0.7	-1.1	4
Cash Flow from Ops. ⓘ	0.3	0.3	-0.1	-0.2	-0.1	-0.3	-0.1	-0.4	-0.2	-4.7	-
Debt/CF from Ops. ⓘ	4.5	5.8	-6.1	-3.8	-14.2	-3.6	-7.7	-3.9	-8.2	-0.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-100%	NA	NA	NA
Adj EPS ⓘ	-225.4%	NA	NA	NA
BVPSⓘ	6.3%	NA	NA	NA
Share Price	9.4%	45.4%	68.9%	134.9%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	1.1	5	-123.2	-144.2	-2869.3	152.9	61.7	60.1	-418.4	-8.4	16.1
Op. Profit Mgn % ⓘ	4.7	5.8	-51.5	0	0	0	0	0	0	0	6.9
Net Profit Mgn % ⓘ	0.3	1.7	-84.4	0	0	0	0	0	0	0	7.5
Debt to Equity ⓘ	0.5	0.7	3.6	21	-23.5	-4.3	-2.6	-1.9	-1.2	0	-
Working Cap Days ⓘ	213	229	460	0	0	0	0	0	0	0	61
Cash Conv. Cycle ⓘ	102	95	310	0	0	0	0	0	0	0	28

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	1.8	-
TTM Sales (₹ Cr.)	57.3	-
BVPS (₹) ⓘ	12.1	-
Reserves (₹ Cr.) ⓘ	5	-
P/BV ⓘ	2.16	-
PE ⓘ	14.36	-

From the Market
52 Week Low / High (₹)	10.56 / 35.52
All Time Low / High (₹)	0.52 / 160.70
Market Cap (₹ Cr.)	61.7
Equity (₹ Cr.)	23.7
Face Value (₹)	10
Industry PE ⓘ	43.4

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Kabra Drugs - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	9.65	7.61	2.01	0	0	0	0	0	0	0
Operating Expenses ⓘ +	9.20	7.17	3.04	0.14	0.05	0.15	0.18	0.34	0.74	1.72
Manufacturing Costs	1.33	1.14	0.24	0	0	0	0	0	0	0
Material Costs	6.52	4.14	1.38	0	0	0	0	0	0	0
Employee Cost	0.68	0.83	1.18	0.03	0	0.05	0.09	0.23	0.40	0.69
Other Costs ⓘ	0.67	1.06	0.24	0.10	0.05	0.10	0.09	0.11	0.34	1.02
Operating Profit ⓘ	0.46	0.44	-1.03	-0.14	-0.05	-0.15	-0.18	-0.34	-0.74	-1.72
Operating Profit Margin (%)	4.7%	5.8%	-51.5%	-	-	-	-	-	-	-
Other Income ⓘ +	0.02	0.11	0.01	0.01	0.02	0	0	0.01	0	0.64
Exceptional Items ⓘ	0	0	-0.95	0	0	0	0	0	0	0
Interest ⓘ	0.18	0.17	0.25	0.01	0	0	0	0	0	0
Depreciation ⓘ	0.24	0.24	0.14	0.03	0.03	0.03	0.01	0	0	0.01
Profit Before Tax ⓘ	0.05	0.14	-2.36	-0.16	-0.06	-0.18	-0.19	-0.34	-0.74	-1.09
Tax ⓘ	0.02	0.01	0	0	0	0	0	0	0	0
Profit After Tax	0.03	0.13	-2.36	-0.16	-0.06	-0.18	-0.19	-0.34	-0.74	-1.09
PAT Margin (%)	0.3%	1.7%	-117.0%	-	-	-	-	-	-	-
Adjusted EPS (₹)	0.1	0.3	-5.4	-0.4	-0.1	-0.4	-0.4	-0.8	-1.7	-0.5
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	2.63	2.55	0.20	0.03	-0.03	-0.21	-0.39	-0.73	-1.47	24.65
Share Capital ⓘ	4.39	4.39	4.39	4.39	4.39	4.39	4.39	4.39	4.39	23.71
Reserves ⓘ	-1.76	-1.84	-4.19	-4.36	-4.42	-4.60	-4.78	-5.12	-5.86	0.95
Debt +	1.28	1.68	0.66	0.67	0.65	0.90	1.03	1.38	1.71	0.44
Long Term Debt	1.18	1.03	0.01	0.02	0	0	0	0	0	0
Short Term Debt	0.10	0.65	0.65	0.65	0.65	0.90	1.03	1.38	1.71	0.44
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	2.79	1.28	0.21	0.19	0.19	0.19	0	0	0	0
Others Liabilities ⓘ	2.47	0.88	0.63	0.59	0.60	0.52	0.10	0.05	4.33	0.14
Total Liabilities ⓘ	9.17	6.39	1.70	1.48	1.41	1.40	0.73	0.70	4.57	25.23
Fixed Assets
Net Fixed Assets ⓘ +	2.73	2.48	0.11	0.08	0.04	0.01	0	0	0	0.04
Gross Block	9.02	2.73	0.17	0.17	0.17	0.17	0.17	0.17	0	0.05
Accumulated Depreciation	6.29	0.24	0.06	0.09	0.13	0.16	0.17	0.17	0	0.01
CWIP ⓘ	0.21	0.21	0	0	0	0	0	0	0	0
Investments ⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	0.32	0.22	0	0	0	0	0	0	0	0
Trade Receivables	5.36	2.95	1.26	1.25	1.25	1.25	0.60	0.60	0.60	0.60
Cash Equivalents ⓘ	0.16	0.09	0.13	0.01	0.01	0.01	0	0	2.67	21.30
Others Assets ⓘ	0.39	0.43	0.20	0.14	0.11	0.13	0.13	0.10	1.30	3.29
Total Assets ⓘ	9.17	6.39	1.70	1.48	1.41	1.40	0.73	0.70	4.57	25.23

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	0.28	0.31	-0.12	-0.18	-0.05	-0.25	-0.13	-0.35	-0.21	-4.71
PBT ⓘ	0.05	0.14	-2.36	-0.16	-0.06	-0.18	-0.19	-0.34	-0.74	-1.09
Adjustment ⓘ	0.41	0.30	1.32	0.03	0.01	0.03	0.01	0	0	0.01
Changes in Working Capital ⓘ	-0.15	-0.12	0.94	-0.04	0	-0.1	0.04	-0.02	0.53	-3.63
Tax Paid ⓘ	-0.02	-0.01	-0.02	-0	0	0	0	0	0	0
Cash Flow From Investing Activity ⓘ +	-0.29	0.01	1.50	0.07	0.06	0	0	0	0	-0.05
Capex	-0.31	-0	1.50	0	0.01	0	0	0	0	-0.05
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0.02	0.01	0	0.07	0.06	0	0	0	0	0
Cash Flow From Financing Activity ⓘ +	-0.27	-0.32	-1.35	-0	-0.02	0.25	0.13	0.36	2.88	23.39
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	2.55	24.66
Net Proceeds from Borrowing ⓘ	0	0	-1.10	0.01	-0.02	0	0	0	0	0
Interest Paid ⓘ	-0.18	-0.17	-0.25	-0.01	-0	0	0	0	0	0
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-0.09	-0.15	0	0	0	0.25	0.13	0.36	0.33	-1.27
Net Cash Flow ⓘ	-0.28	-0	0.04	-0.10	0	-0	-0.01	0	2.67	18.63

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	1.05	5.02	-171.4	-144.2	N/A	N/A	N/A	N/A	N/A	-9.36
ROCE (%)	5.81	7.49	-80.09	-19.67	N/A	N/A	N/A	N/A	N/A	-7.78
Asset Turnover Ratio	1.09	0.99	0.5	0	0	0	0	0	0	0
PAT to CFO Conversion(x)	9.33	2.38	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	185.90	197.10	383.20	0	0	0	0	0	0	0
Inventory Days	13.80	12.80	0	0	0	0	0	0	0	0
Payable Days	136.20	179.20	196.10	0	0	0	0	0	0	0

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Kabra Drugs Ltd FAQs

The current trading price of Kabra Drugs on 30-Apr-2026 16:59 is ₹26.03.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 29-Apr-2026 the market cap of Kabra Drugs stood at ₹61.71 Cr

The latest P/E ratio of Kabra Drugs as of 29-Apr-2026 is 14.36.

The latest P/B ratio of Kabra Drugs as of 29-Apr-2026 is 2.16.

The 52-week high of Kabra Drugs is ₹35.52 and the 52-week low is ₹10.56.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Kabra Drugs is ₹57.33 ( Cr.) .

About Kabra Drugs Ltd

Kabra Drugs Ltd. is a limited company incorporated under the Companies Act, 1956 on August 22, 1989 having its registered office at 270 Shastri Market Indore, MP. The company is a public limited Company and its shares are listed on Bombay stock exchange (BSE).

Business area of the company

The company is presently engaged in the business of Permaculture manufacturing and trading in pharma related products.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Kabra Drugs Ltd (524322) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Kabra Drugs Share Price